Ayala Pharmaceuticals, Inc. financial data

Symbol
ADXS on OTC
Industry
Pharmaceutical Preparations
Location
9 Deer Park Drive, Suite K 1, Monmouth Junction, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Advaxis, Inc. (to 1/13/2023), GREAT EXPECTATIONS & ASSOCIATES INC (to 1/5/2005)
Latest financial report
10-K - Q4 2023 - Apr 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 77 % -89.4%
Debt-to-equity 12.1 % -34.7%
Return On Equity 963 %
Return On Assets -339 % -126%
Operating Margin -19.2K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.6M shares
Common Stock, Shares, Outstanding 11.9M shares +349%
Entity Public Float 3.7M USD
Common Stock, Value, Issued 12K USD +300%
Weighted Average Number of Shares Outstanding, Basic 6.02M shares +108%
Weighted Average Number of Shares Outstanding, Diluted 4.78M shares +64.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 209K USD -76.3%
Revenue from Contract with Customer, Excluding Assessed Tax 250K USD -81.8%
Research and Development Expense 24.1M USD -13.5%
General and Administrative Expense 12.2M USD +25.1%
Operating Income (Loss) -36.3M USD +3.3%
Nonoperating Income (Expense) -143K USD -14400%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -52M USD -38.9%
Income Tax Expense (Benefit) -3.91M USD -770%
Net Income (Loss) Attributable to Parent -48.1M USD -26.5%
Earnings Per Share, Basic -7.99 USD/shares +39.1%
Earnings Per Share, Diluted -1.53 USD/shares +56.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.88M USD +103%
Other Assets, Current 172K USD +3340%
Assets, Current 7.53M USD +136%
Property, Plant and Equipment, Net 540K USD -43.8%
Operating Lease, Right-of-Use Asset 102K USD -93%
Intangible Assets, Net (Excluding Goodwill) 3.9M USD
Goodwill 4.5M USD
Other Assets, Noncurrent 212K USD +1827%
Assets 16.6M USD +113%
Accounts Payable, Current 22K USD -74.7%
Employee-related Liabilities, Current 786K USD -20.9%
Accrued Liabilities, Current 2.15M USD -24.2%
Liabilities, Current 25M USD +303%
Operating Lease, Liability, Noncurrent 9K USD -99.3%
Liabilities 2.3M USD -70.8%
Retained Earnings (Accumulated Deficit) -197M USD -32.2%
Stockholders' Equity Attributable to Parent -24.4M USD -2122%
Liabilities and Equity 16.6M USD +113%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.74M USD +32.5%
Net Cash Provided by (Used in) Financing Activities 21.2M USD +48084%
Common Stock, Shares Authorized 170M shares +354%
Common Stock, Shares, Issued 11.9M shares +341%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.4M USD
Deferred Tax Assets, Valuation Allowance 136M USD +251%
Deferred Tax Assets, Gross 136M USD +249%
Operating Lease, Liability 175K USD -90%
Depreciation 44K USD +46.7%
Lessee, Operating Lease, Liability, to be Paid 180K USD
Property, Plant and Equipment, Gross 1.35M USD -16.5%
Operating Lease, Liability, Current 166K USD -60.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 171K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 308K USD
Deferred Tax Assets, Operating Loss Carryforwards 38.3M USD +16.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.77M USD +32.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 308K USD
Operating Lease, Payments 109K USD 0%
Additional Paid in Capital 173M USD +16.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 418K USD +20.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%